Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01475058 · ClinicalTrials.gov registry record · Phase 1
CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT01475058 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 1 participants.
The verdict
NCT01475058, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase I/II trial studies the safety and toxicity of post-transplant treatment with donor T cells engineered to express a chimeric antigen receptor (CAR) targeting CD19 in patients who have had a matched related allogeneic hematopoietic stem cell transplant for a CD19+ B cell malignancy.
Interventions
- BIOLOGICAL allogeneic cytomegalovirus-specific cytotoxic T lymphocytes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2012-04 |
| Est. Completion | 2014-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01475058
The ClinicalTrials.gov registry entry for NCT01475058 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which allogeneic cytomegalovirus-specific cytotoxic T lymphocytes is the first listed.
NCT01475058 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01475058 about?
NCT01475058 is a clinical study titled "CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant". This phase I/II trial studies the safety and toxicity of post-transplant treatment with donor T cells engineered to express a chimeric antigen receptor (CAR) targeting CD19 in patients who have had a matched related allogeneic hematopoietic stem cell transplant for a CD19+ B cell malignancy.
What is the current status of trial NCT01475058?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2012-04. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01475058?
The interventions under investigation include: allogeneic cytomegalovirus-specific cytotoxic T lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT01475058?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.